Beyond Androgen Blockade - Exploring New Pathways for Treating mCRPC and mHSPC VL

The Current Treatment Landscape in Metastatic Hormone-Sensitive Prostate Cancer - Andrew Armstrong

Details
Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC. Part of an Independent Medical Education Initiative Supported by LOXO@Lilly Biographies: Andrew Armstrong, MD, Professor of Medicine, Professor in Surgery, Professor in Pharmacology and Cancer Biology, Director of Research, Duke University, Durham, NC Alicia Morgans, MD, MPH , Genitourinary Medical Oncologist...

PSMA PET as a Biomarker for Advanced Prostate Cancer - Oliver Sartor

Details
Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC. Part of an Independent Medical Education Initiative Supported by LOXO@Lilly Biographies: A. Oliver Sartor, MD, Disease Group Leader GU Cancers, Director of Radiopharmaceutical Trials, Mayo Clinic, Rochester, MN Neal D. Shore, MD, FACS, Medical Director, Carolina Urologic Research Center, Atlantic Urology Clin...

2023 Key Learnings in mCRPC Treatments – Alicia Morgans

Details
Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC Part of an Independent Medical Education Initiative Supported by LOXO@Lilly Biographies: Alicia Morgans, MD, MPH , Genitourinary Medical Oncologist, Medical Director of Survivorship Program at Dana-Farber Cancer Institute, Boston, Massachusetts Rana R. McKay, Medical Oncologist, Associate Professor, University...

Treatment Decision Making in mHSPC: The Medical Oncologist and Patient “What the Patient Needs to Know” About this Disease and Treatment Options? - Brenda Martone

Details
Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC Part of an Independent Medical Education Initiative Supported by LOXO@Lilly Biographies: Brenda Martone, MSN, ANP-BC, AOCNP, Adult Nurse Practitioner, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL Alicia Morgans, MD, MPH , Genitourinary Medical Oncologist, Medical Director...

Treatment Decision Making in mCRPC: The Urologist and Patient “What the Patient Needs to Know” About His Disease and Treatment Options? - Brenda Martone

Details
Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC Part of an Independent Medical Education Initiative Supported by LOXO@Lilly Biographies: Brenda Martone, MSN, ANP-BC, AOCNP, Adult Nurse Practitioner, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL Neal D. Shore, MD, FACS, Medical Director, Carolina Urologic Research Center...

Multidisciplinary Approach in the Treatment of Metastatic Prostate Cancer - Robert Dreicer

Details
Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC Part of an Independent Medical Education Initiative Supported by LOXO@Lilly Biographies: Robert Dreicer, MD, MS, MACP, FASCO, Head, Medical Oncology Section, Deputy Director University of Virginia Comprehensive Cancer Center, Associate Director for Clinical Research, Co-Director Paul Mellon Urologic Oncology C...